Royal Philips has previewed updates in its product portfolio and new data due to be shared at the Transcatheter Cardiovascular Therapeutics annual meeting (TCT 2021, 4–6 November, Orlando USA and virtual) this week.
The new updates are aimed at innovating and advancing procedures including percutaneous coronary intervention (PCI), Philips said in a press release, and added that the company is putting a spotlight on new clinical data being presented at TCT that shows how minimally-invasive techniques are helping to innovate interventional procedures and improve patient outcomes.
“Interventional physicians seek ever-more precise, accurate and efficient tools to decide, guide, treat and confirm the right therapy for the right patient at the point of care,” said Chris Landon, senior vice president and general manager, Image Guided Therapy Devices at Philips. “At this year’s TCT, we’re showing how we are continuously innovating and expanding our integrated ecosystem of interventional imaging systems and diagnostic and therapeutic devices to provide clinicians with a complete solution, from diagnosis to treatment and therapy monitoring, to optimise their workflow and the treatment of each individual patient.”
Technologies on display will include the new Philips interventional applications platform, IntraSight Mobile, which brings together imaging and physiology applications on a mobile system for coronary and peripheral artery disease therapy. The IntraSight platform allows interventional cardiologists to perform intravascular ultrasound (IVUS) imaging and physiologic measurements of fractional flow reserve (FFR) and instant wave-free ratio (iFR) to accurately identify the location of lesions causing ischaemia.
The newly designed Philips scoring balloon catheter RX, AngioSculpt Evo, and the new laser system, Nexcimer, were also highlighted by the company in a press release.
Clinical data to be presented at TCT 2021 include five-year outcomes of the iFR-SWEDEHEART trial, presented by Matthias Götberg (Skane University Hospital, Lund, Sweden), and large-scale study outcomes on use of IVUS by Eric A Secemsky (Beth Israel Deaconess Medical Center and Assistant Professor of Medicine at Harvard Medical School in Boston, USA).